Two active pharmaceutical ingredient production lines of SaiTuo Bio's controlled subsidiary, Shandong Sirui Pharmaceutical Co., Ltd., have passed the drug GMP compliance inspection. The triamcinolone acetonide API production line met the requirements during the inspection from March 25 to 27, 2026, and the betamethasone API production line also met the requirements during the inspection from May 13 to 15, 2026. Passing this inspection indicates that the relevant workshops and production lines comply with good manufacturing practices for drugs, helping the company maintain stable product quality and production capacity to meet market demand. In the first quarter of 2026, SaiTuo Bio achieved revenue of 328 million yuan and a net profit attributable to the parent company of 3.62 million yuan.
Shandong Sito Bio-technology Co LtdSubsidiary's two API production lines passed GMP compliance inspection, ensuring regulatory compliance and stable production.
Its two API production lines passed GMP compliance inspection, confirming adherence to good manufacturing practices.